ArticlePhysics and imaging in radiation oncology2026
Development of a cost-effective end-to-end commissioning test for simulation-omitted direct-to-unit adaptive radiotherapy.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Direct-to-Unit (simulation-omitted) adaptive radiotherapy (ART) enables same-day treatment by generating treatment plans from diagnostic images, eliminating the need for computed tomography (CT) simulation. These workflows rely on online plan re-optimization to account for anatomical, CT-number, and setup variations. However, no standardized end-to-end (E2E) credentialing protocol currently exists to validate the accuracy of Direct-to-Unit ART. Although customized ART phantoms are available, they are often costly, and impractical for one-time commissioning. To address this gap, we developed a low-cost E2E commissioning framework using a commercially available CIRS ZEUS phantom to verify workflow accuracy while minimizing financial burden. Materials and Methods: E2E commissioning tests were performed on Varian Ethos and Elekta Unity systems using a CIRS ZEUS phantom (Model 008Z) equipped with inserts for ionization chamber point-dose and planar film measurements. The ionization chamber and Gafchromic EBT4 films were independently cross-calibrated on an Elekta Versa linear accelerator. Pseudo-diagnostic CT datasets were generated and deformed to simulate anatomical variation. Pre-plans (2 Gy × 30 fractions) were created and delivered across three ART fractionation schemes. Point-dose measurements were compared with system-reported values, and planar dose distributions were evaluated using global gamma analysis. Results: All point-dose differences were within 3% (for high-dose regions) or 3 cGy (for low-dose regions) of the system-reported values. All planar film measurements achieved gamma pass rates exceeding 90% using 3%/3 mm criterion. Conclusion: This cost-effective E2E approach provides a practical commissioning solution for Direct-to-Unit ART, supporting safe clinical implementation and facilitating cross-institutional standardization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.